Template talk:Editnotices/Page/Influenza

There is now a 3rd class of anti-Influenza drugs On October 24, 2018 the U.S. FDA approved Xofluza (Baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. It prevents replication by inhibiting the cap-dependent endonuclease activity of the viral polymerase.[6] It achieves this by inhibiting the process known as cap snatching[7], which is a mechanism exploited by viruses to hijack the host mRNA transcription system to allow synthesis of viral RNAs.

[6] Dias, Alexandre; Bouvier, Denis; Crépin, Thibaut; McCarthy, Andrew A.; Hart, Darren J.; Baudin, Florence; Cusack, Stephen; Ruigrok, Rob W. H. (2009). "The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit". Nature. 458 (7240): 914–918. doi:10.1038/nature07745. ISSN 0028-0836. [7] "Cap snatching". (Craig Werner, cwerner@montefiore.org)